Staphylococcus aureus antigens and challenges in vaccine development

Expert Review of Vaccines

Volumn 7, Issue 6, 2008, Pages 805-815

  Middleton, John R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Antigen; Immunotherapy; Staphylococcus aureus; Vaccine; Virulence factor

Indexed keywords

ALTASTAPH; ALUMINUM HYDROXYPHOSPHATE SULFATE; ALUMINUM POTASSIUM SULFATE; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIN; CAPSULAR POLYSACCHARIDE 5 CONJUGATED WITH HUMAN SERUM ALBUMIN; CAPULAR POLYSACCHARIDE 8; CLUMPING FACTOR A; CLUMPING FACTOR B; COLLAGEN BINDING PROTEIN; COLLAGEN BINDING PROTEIN FIBRONECTIN BINDING PROTEIN FUSION PROTEIN; DEACETYLATED POLY N ACETYL BETA(1-6)GLUCOSAMINE DIPHTHERIA TOXOID CONJUGATE; FIBRONECTIN BINDING PROTEIN; FIBRONECTIN BINDING PROTEIN A; FIBRONECTIN BINDING PROTEIN B; FIBRONECTIN BINDING PROTEIN STAPHYLOCOCCUS PROTEIN A FUSION PROTEIN IMMUNOSTIMULATING COMPLEX; FREUND ADJUVANT; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; IRON REGULATED SURFACE DETERMINANT A; ISCOM; LYSIGIN; PAGIBAXIMAB; PANTON VALENTINE LEUKOCIDIN; POLY N ACETYL BETA(1-6)GLUCOSAMINE; POLY N SUCCINYL BETA (1-6)GLUCOSAMINE DIPHTHERIA TOXOID CONJUGATE; RECOMBINANT PROTEIN; SERINE ASPARTATE REPEAT PROTEIN; STAPHYLOCOCCUS PROTEIN A; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERONATE; VIRULENCE FACTOR;

ANTIBODY TITER; CATTLE DISEASE; CLINICAL TRIAL; COMMUNICABLE DISEASE; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; CATTLE; CATTLE DISEASES; HUMANS; MASTITIS, BOVINE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 49449089910     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.6.805     Document Type: Review

References (86)

1. Shinefield HR, Black S. Prevention of Staphylococcus aureus infections: advances in vaccine development. Expert Rev. Vaccines 4(5), 669-676 (2005).
2. Sutra L, Poutrel B. Virulence factors involved in the pathogenesis of bovine intramammary infections due to Staphylococcus aureus. J. Med. Microbiol. 40(2), 79-89 (1994).
3. Paape MJ, Wergin WP, Guidry AJ et al. Phagocytic defense of the ruminant mammary gland. Adv. Exp. Med Biol. 137, 555-578 (1981).
4. Kent GM, Newbould FH. Phagocytosis and related phenomena in polymorphonuclear leukocytes from cow's milk. Can. J. Comp. Med. 33(3), 214-219 (1969).
5. Paape MJ, Guidry AJ, Kirk ST et al. Measurement of phagocytosis of 32P-labeled Staphylococcus aureus by bovine leukocytes: lysostaphin digestion and inhibitory effect of cream. Am. J. Vet. Res. 36(12), 1737-1743 (1975).
6. 2 on phagocytosis by ovine polymorphonuclear leucocytes. Immunology 31(2), 159-165 (1976).
7. Guidry AJ, Berning LM, Hambleton CN. Opsonization of Staphylococcus aureus by bovine immunoglobulin isotypes. J. Dairy Sci. 76(5), 1285-1289 (1993).
8. Barrio MB, Rainard P, Gilbert FB et al. Assessment of the opsonic activity of purified bovine sIgA following intramammary immunization of cows with Staphylococcus aureus. J. Dairy Sci. 86(9), 2884-2894 (2003).
9. Bannerman DD, Paape MJ, Lee JW et al. Escherichia coli and Staphylococcus aureus elicit differential innate immune responses following intramammary infection. Clin. Diagn. Lab. Immunol. 11(3), 463-472 (2004).
10. Hermans K, Devriese LA, Haesebrouck F. Staphylococcus. In: Pathogenesis of Bacterial Infections in Animals (3rd Edition). Gyles CL, Prescott JF, Songer JG, Thoen CO (Eds). Blackwell Publishing, Ames, IA, USA 43-55 (2004).
11. Peterson PK, Wilkinson BJ, Youngki K et al. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect. Immun. 19(3), 943-939 (1978).
12. Peterson PK, Wilkinson BJ, Youngki K et al. The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J. Clin. Invest. 61(3), 597-609 (1978).
13. Watson DL. Vaccination against experimental staphylococcal mastitis in dairy heifers. Res. Vet. Sci. 53(3), 346-353 (1992).
14. Williams JM, Mayerhofer HJ, Brown RW. Clinical evaluation of a Staphylococcus aureus bacterin (polyvalent somatic antigen). Vet. Med. Small Anim. Clin. 61(8), 789-793 (1966).
15. Williams JM, Shipley GR, Smith GL et al. A clinical evaluation of Staphylococcus aureus bacterin in the control of staphylococcal mastitis in cows. Vet. Med. Small Anim. Clin. 70(5), 587-594 (1975).
16. Brock JH, Steel ED, Reiter B. The effect of intramuscular and intramammary vaccination of cows on antibody levels and resistance to intramammary infection by Staphylococcus aureus. Res. Vet. Sci. 19(2), 152-158 (1975).
17. Middleton JR, Ma J, Rinehart CL et al. Efficacy of different Lysigin® formulations in the prevention of Staphylococcus aureus intramammary infection in dairy heifers. J. Dairy Res. 73(1), 10-19 (2006).
18. Luby CD, Middleton JR, Ma J et al. Characterization of the antibody isotype response in serum and milk of heifers vaccinated with a Staphylococcus aureus bacterin (Lysigin™). J. Dairy Res. 74(2), 239-246 (2007).
19. Leitner G, Lubashevsky E, Trainin Z. Staphylococcus aureus vaccine against mastitis in dairy cows, composition and evaluation of its immunogenicity in a mouse model. Vet. Immunol. Immunopathol. 93(3-4), 159-167 (2003).
20. Leitner G, Lubashevsky E, Glickman A et al. Development of a Staphylococcus aureus vaccine against mastitis in dairy cows I. Challenge trials. Vet. Immunol. Immunopathol. 93(3-4), 31-38 (2003).
21. Leitner G, Yadlin N, Lubashevsky E et al. Development of a Staphylococcus aureus vaccine against mastitis in dairy cows II. Field trial. Vet. Immunol. Immunopathol. 93(3-4), 153-158 (2003).
22. Lee JW, O'Brien CN, Guidry AJ et al. Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosis. Can. J. Vet. Res. 69(1), 11-18 (2005).
23. Sears PM, Belschner AP. Alternative management and economic consideration in Staphylococcus aureus elimination programs. Presented at: 38th National Mastitis Council Annual Meeting. Arlington, VA, USA, 14 -17 February 1999.
24. Rizzo C, Brancaccio G, De Vito D et al. Efficacy of autovaccination therapy on post-coronary artery bypass grafting methicillin-resistant Staphylococcus aureus mediastinitis. Interact. Cardiovasc. Thorac. Surg. 6(2), 228-229 (2007).
25. Karakawa WW, Vann WF. Capsular polysaccharides of Staphylococcus aureus. In: Seminars in Infectious Disease. Neinstein L, Fields BN (Eds). Thieme-Stratton, NY, USA 285-293 (1982).
26. Sompolinsky D, Samra Z, Karakawa WW et al. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J. Clin. Microbiol. 22(5), 828-834 (1985).
27. Guidry A, Fattom A, Patel A et al. Serotyping scheme for Staphylococcus aureus isolated from cows with mastitis. Am. J. Vet. Res. 59(12), 1537-1539 (1998).
28. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 17(1), 218-234 (2004).
29. Jones C. Revised structures for the capsular polysaccharides from Staphylococcus aureus types 5 and 8, components of novel glycoconjugate vaccines. Carbohydr. Res. 340(6), 1097-1106 (2005).
30. Guidry A, Fattom A, Patel A et al. Prevalence of capsular serotypes among Staphylococcus aureus isolates from cows with mastitis in the United States. Vet. Microbiol. 59(1), 53-58 (1997).
31. Kenny K, Tollersrud T. Questions uniqueness of surface polysaccharide. Am. J. Vet. Res. 60(5), 530 (1999).
32. Verdier I, Durand G, Bes M et al. Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests. J. Clin. Microbiol. 45(3), 725-729 (2007).
33. Cocchiaro JL, Gomez MI, Risley A et al. Molecular characterization of the capsule locus from non-typeable Staphylococcus aureus. Mol. Microbiol. 59(3), 948-960 (2006).
34. Tollersrud T, Zernichow L, Anderson SR et al. Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle. Vaccine 19(28-29), 3896-3903 (2001).
35. Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346(7), 491-496 (2002). • Phase III clinical trial of StaphVAX®.
36. Fattom AI, Horwith G, Fuller S et al. Development of StaphVAX® , a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to Phase III clinical trials. Vaccine 22(7), 880-887 (2004).
37. Fattom A, Fuller A, Propst M et al. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX® ) in hemodialysis patients. Vaccine 23(5), 656-663 (2004).
38. Robbins JB, Schneerson R, Horwith G et al. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. Am. Heart J. 147(4), 593-598 (2004).
39. Nour El-Din AN, Shkreta L, Talbot BG et al. DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. Vaccine 24(12), 1997-2006 (2006).
40. Gaudreau MC, Lacasse P, Talbot BG. Protective immune responses to a multi-gene DNA vaccine against Staphylococcus aureus. Vaccine 25(5), 814-824 (2007).
41. Brouillette E, Lacasse P, Shkreta L et al. DNA immunization against clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 20(17-18), 2348-2357 (2002).
42. Therrien R, Lacasse P, Grondin G et al. Lack of protection of mice against Staphylococcus aureus despite a significant immune response to immunization with a DNA vaccine encoding collagen-binding protein. Vaccine 25(27), 5053-5061 (2007).
43. Schaffer AC, Solinga RM, Cocchiaro J et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 74(4), 2145-2153 (2006).
44. Zhou H, Xiong ZY, Li HP, Zhengy YL, Jiang XO. An immunogenicity study of a newly fusion protein Can-FnBP vaccinated against Staphylococcus aureus in a mice model. Vaccine 24(22), 4830-4837 (2006).
45. Nelson L, Flock JI, Hook M et al. Adhesins in staphylococcal mastitis as vaccine components. Flem. Vet. J. 62(Suppl. 1), 111-125 (1990).
46. McKenney D, Pouliot KL, Wang Y et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284(5419), 1523-1527 (1999).
47. Maira-Litran T, Kropec A, Goldmann DA et al. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide. Vaccine 22(7), 872-879 (2004).
48. Maira-Litran T, Kropec A, Goldmann DA et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-β-(1- 6)-glucosamine. Infect. Immun. 73(10), 6752-6762 (2005).
49. Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74(4), 2215-2223 (2006).
50. Stranger-Jones YK, Bae T, Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl Acad. Sci. USA 103(45), 16942-16947 (2006). •• Promising approach to vaccination, especially since some of the antigens studied have been shown to be important in the pathogenesis of human infection and colonization.
51. Senna JP, Roth DM, Oliveira JS et al. Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine. Vaccine 21(19-20), 2661-2666 (2003).
52. Roth DM, Senna JPM, Machado DC. Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillinresistant Staphylococcus aureus. Genet. Mol. Res. 5(3), 503-512 (2006).
53. Ohwada A, Sekiya M, Hanaki H et al. DNA vaccination by mecA sequence evokes an antibacterial immune response against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 44(6), 767-774 (1999).
54. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205(2), 287-294 (2008). • Potential approach to the prevention of staphylococcal pneumonia.
55. DeLeo FR, Otto M. An antidote for Staphylococcus aureus pneumonia? J. Exp. Med. 205(2), 271-274 (2008).
56. Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect. Immun. 75(2), 1040-1044 (2007).
57. Adlam C, Ward PD, McCartney CA et al. Effect of immunization with highly purified α- and β-toxins on staphylococcal mastitis in rabbits. Infect. Immun. 17(2), 250-256 (1977).
58. Menzies BE, Kernodle DS. Passive immunization with antiserum to a nontoxic ?-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect. Immun. 64(5), 1839-1841 (1996).
59. Hume EB, Dajcs JJ, Moreau JM et al. Immunization with ?-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect. Immun. 68(10), 6052-6055 (2000).
60. Hu DL, Omoe K, Sasaki S et al. Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J. Infect. Dis. 188(5), 743-752 (2003).
61. Cui JC, Hu DL, Lin YC et al. Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. FEMS Immunol. Med. Microbiol. 45(1), 45-51 (2005).
62. Hu DL, Omoe K, Narita K et al. Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. Microbes Infect. 8(14-15), 2841-2848 (2006).
63. Parsonnet J, Hansmann MA, Delaney ML et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J. Clin. Microbiol. 43(9), 4628-4634 (2005).
64. Chang BS, Moon JS, Kang H et al. Protective effects of recombinant staphylococcal enterotxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle. Vaccine 26(17), 2081-2091 (2008).
65. Goji N, Potter AA, Perez-Casal J. Characterization of two proteins of Staphylococcus aureus isolated from bovine clinical mastitis with homology to glyceraldehyde-3-phosphate dehydrogenase. Vet. Microbiol. 99(3-4), 269-279 (2004).
66. Fontaine MC, Perez-Casal J, Song XM et al. Immunisation of dairy cattle with recombinant Streptococcus uberis GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge. Vaccine 20(17-18), 2278-2286 (2002).
67. Perez-Casal J, Prysliak T, Kerro-Dego O et al. Immune responses to a Staphylococcus aureus GapC/B chimera and its potential use as a component of a vaccine for S. aureus mastitis. Vet. Immunol. Immunopathol. 109(1-2), 85-97 (2006).
68. Kerro-Dego O, Prysliak T, Potter AA et al. DNA-protein immunization against GapB and GapC proteins of a mastitis isolate of Staphylococcus aureus. Vet. Immunol. Immunopathol. 113(1-2), 125-138 (2006).
69. Balaban N, Goldkorn T, Nahn RT et al. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science 280(5362), 438-440 (1998).
70. Yang G, Gao Y, Dong J et al. A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections. J. Biol. Chem. 280(29), 27431-27435 (2005).
71. Yang G, Gao Y, Dong J et al. A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococcal infection. Vaccine 24(8), 1117-1123 (2006).
72. Pellegrino M, Giraudo J, Raspanti C et al. Experimental trial in heifers vaccinated with Staphylococcus aureus avirulent mutant against bovine mastitis. Vet. Microbiol. 127(1-2), 186-190 (2008).
73. Bogni C, Segura M, Giraudo et al. Avirulence and immunogenicity in mice of a bovine mastitis Staphylococcus aureus mutant. Can. J. Vet. Res. 62(4), 293-298 (1998).
74. Buzzola FR, Barbagelata MS, Caccuri RL et al. Attenuation and persistence of and ability to induce protective immunity to a Staphylococcus aureus aroA mutant in mice. Infect. Immun. 74(6), 3498-3506 (2006).
75. Weisman LE. Antibody for the prevention of neonatal nosocomial staphylococcal infection: a review of the literature. Arch. Pediatr. 14(Suppl. 1), S31-S34 (2007).
76. Ma J, Cocchiaro J, Lee JC. Evaluation of serotypes of Staphylococcus aureus strains used in the production of a bovine mastitis bacterin. J. Dairy Sci. 87(1), 178-182 (2004)
77. Pankey JW, Boddie NT, Watts JL et al. Evaluation of protein A and a commercial bacterin as vaccines against Staphylococcus aureus mastitis by experimental challenge. J. Dairy Sci. 68(3), 726-731 (1985).
78. Nickerson SC, Owens WE, Tomita GM et al. Vaccinating dairy heifers with a Staphylococcus aureus bacterin reduces mastitis at calving. Large Animal Practice 20, 16-28 (1999).
79. Fox LK, Chester ST, Hallberg JW et al. Survey of intramammary infections in dairy heifers at breeding age and first parturition. J. Dairy Sci. 78(7), 1619-1628 (1995).
80. Risley AL, Loughman A, Cywes-Bentley C et al. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J. Infect. Dis. 196(6), 919-927 (2007).
81. Dryla A, Prustomersky S, Glebmann D et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab Immunol. 12(3), 387-398 (2005). •• Defines vaccine targets.
82. Clarke SR, Brummell KJ, Horsburgh MJ et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 193(8), 1098-1108 (2006). •• Defines vaccine targets.
83. Weichhart T, Horky M, Sollner J et al. Functional selection of vaccine candidate peptides from Staphylococcus aureus wholegenome expression libraries in vitro. Infect. Immun. 71(8), 4633-4641 (2003). •• Defines vaccine targets.
84. StaphVAX® www.nabi.com/pipeline/pipeline.php?id=1
85. Staphylococcus epidermidis (PS-1 and GP-1) www.nabi.com/pipeline/ pipeline.php?id=18
86. Aurexis®: Staphylococcus aureus www.inhibitex.com/Pipeline/ Aurexis.htm